Home › A risky biotech stock's rise and fall
 

Keywords :   


A risky biotech stock's rise and fall

2015-03-14 00:32:54| Biotech - Topix.net

Biotech firm Neuralstem's stock sank by 37% Thursday, to $2.37 a share, after it reported disappointing results from a clinical trial. In January 2014, a 41-year-old mother named April Moundzouris who had been diagnosed with amyotrophic lateral sclerosis, or Lou Gehrig's disease, blogged that she was responding well to treatment in a clinical trial.

Tags: fall rise stocks biotech

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.10Weekly Recap: BASF, Beckers, Allnex, Sherwin-Williams Top This Weeks Stories
05.10Hurricane Kirk Graphics
05.10Hurricane Kirk Forecast Discussion Number 24
05.10Hurricane Kirk Wind Speed Probabilities Number 24
05.10Hurricane Kirk Forecast Advisory Number 24
05.10Hurricane Kirk Public Advisory Number 24
05.10Summary for Hurricane Kirk (AT2/AL122024)
05.10Hurricane Leslie Graphics
More »